BTG3 and Jeune syndrome: In our study, we used a cut-off of 1:40 for ANA IIFA on HEp-2 cells as well as previous studies, and we found that ANA prevalence was (50.8%) IIFA on HEp-2 cells, is considered the most reliable method for ANA screening.[23,26]The presence of other nonthyroid autoantibodies in ATD patients remains controversial.